Patent 12129293 was granted and assigned to Janssen Biotech on October, 2024 by the United States Patent and Trademark Office.
A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.